Cargando…

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib

Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Botrus, Gehan, Roe, Denise, Jameson, Gayle S., Junior, Pedro Luiz Serrano Uson, Korn, Ronald Lee, Caldwell, Lana, Bargenquast, Taylor, Miller, Max, Borazanci, Erkut Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/
https://www.ncbi.nlm.nih.gov/pubmed/36359225
http://dx.doi.org/10.3390/biomedicines10112705
_version_ 1784836070831030272
author Botrus, Gehan
Roe, Denise
Jameson, Gayle S.
Junior, Pedro Luiz Serrano Uson
Korn, Ronald Lee
Caldwell, Lana
Bargenquast, Taylor
Miller, Max
Borazanci, Erkut Hasan
author_facet Botrus, Gehan
Roe, Denise
Jameson, Gayle S.
Junior, Pedro Luiz Serrano Uson
Korn, Ronald Lee
Caldwell, Lana
Bargenquast, Taylor
Miller, Max
Borazanci, Erkut Hasan
author_sort Botrus, Gehan
collection PubMed
description Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents patients treated at the HonorHealth Research Institute with a diagnosis of HRD MPC who received Mitomycin C (MMC) treatment from January 2013 until July 2018. Five HRD MPC patients treated with MMC were evaluated. All patients received at least one course of treatment. Mean age at MMC treatment initiation was 58 years. There were 3 females and 2 males. All patients had tumors that progressed on platinum-based chemotherapy, four patients had previous exposure to Olaparib. The median PFS was 10.1 months, and the median OS was 12.3 months. Responses were observed only in patients harboring BRCA2 mutations, no response was observed in the PALB2 mutation carrier. MMC in this heavily previously treated PC was safe, with overall manageable grade 2 gastrointestinal toxicities including nausea and vomiting, and G3 hematological toxicities including anemia and thrombocytopenia. Pancreatic cancer patients with HRD may benefit from MMC treatment. Further clinical investigation of MMC in pancreatic cancer is warranted.
format Online
Article
Text
id pubmed-9687686
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96876862022-11-25 Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib Botrus, Gehan Roe, Denise Jameson, Gayle S. Junior, Pedro Luiz Serrano Uson Korn, Ronald Lee Caldwell, Lana Bargenquast, Taylor Miller, Max Borazanci, Erkut Hasan Biomedicines Article Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents patients treated at the HonorHealth Research Institute with a diagnosis of HRD MPC who received Mitomycin C (MMC) treatment from January 2013 until July 2018. Five HRD MPC patients treated with MMC were evaluated. All patients received at least one course of treatment. Mean age at MMC treatment initiation was 58 years. There were 3 females and 2 males. All patients had tumors that progressed on platinum-based chemotherapy, four patients had previous exposure to Olaparib. The median PFS was 10.1 months, and the median OS was 12.3 months. Responses were observed only in patients harboring BRCA2 mutations, no response was observed in the PALB2 mutation carrier. MMC in this heavily previously treated PC was safe, with overall manageable grade 2 gastrointestinal toxicities including nausea and vomiting, and G3 hematological toxicities including anemia and thrombocytopenia. Pancreatic cancer patients with HRD may benefit from MMC treatment. Further clinical investigation of MMC in pancreatic cancer is warranted. MDPI 2022-10-26 /pmc/articles/PMC9687686/ /pubmed/36359225 http://dx.doi.org/10.3390/biomedicines10112705 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Botrus, Gehan
Roe, Denise
Jameson, Gayle S.
Junior, Pedro Luiz Serrano Uson
Korn, Ronald Lee
Caldwell, Lana
Bargenquast, Taylor
Miller, Max
Borazanci, Erkut Hasan
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title_full Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title_fullStr Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title_full_unstemmed Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title_short Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
title_sort mitomycin c in homologous recombination deficient metastatic pancreatic cancer after disease progression on platinum-based chemotherapy and olaparib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/
https://www.ncbi.nlm.nih.gov/pubmed/36359225
http://dx.doi.org/10.3390/biomedicines10112705
work_keys_str_mv AT botrusgehan mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT roedenise mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT jamesongayles mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT juniorpedroluizserranouson mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT kornronaldlee mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT caldwelllana mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT bargenquasttaylor mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT millermax mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib
AT borazancierkuthasan mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib